(0.19%) 5 531.75 points
(0.19%) 39 544 points
(0.14%) 19 956 points
(0.45%) $81.91
(-1.27%) $2.57
(0.10%) $2 341.90
(-0.12%) $29.53
(-1.91%) $994.70
(-0.33%) $0.930
(-0.41%) $10.63
(-0.22%) $0.789
(1.25%) $86.80
Live Chart Being Loaded With Signals
Provectus Biopharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing immunotherapy medicines based on halogenated xanthenes...
Stats | |
---|---|
Dagens volum | 239 713 |
Gjennomsnittsvolum | 199 596 |
Markedsverdi | 53.28M |
EPS | $-0.00120 ( Q1 | 2024-05-14 ) |
Neste inntjeningsdato | ( $0 ) 2024-08-12 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E |
-12.70 (Sector) 0 (Industry) 0 |
ATR14 | $0.00300 (2.38%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-06-20 | Pershing Edward | Buy | 0 | 8% Unsecured Convertible Promissory Note |
2024-06-15 | Pershing Edward | Buy | 47 190 | Series D-1 Convertible Preferred Stock |
2024-06-15 | Pershing Edward | Sell | 0 | 8% Unsecured Convertible Promissory Note |
2024-05-26 | Pershing Edward | Buy | 18 876 | Series D-1 Convertible Preferred Stock |
2024-05-26 | Pershing Edward | Sell | 0 | 8% Unsecured Convertible Promissory Note |
INSIDER POWER |
---|
100.00 |
Last 100 transactions |
Buy: 14 428 113 | Sell: 0 |
Provectus Korrelasjon
10 Mest positive korrelasjoner |
---|
10 Mest negative korrelasjoner |
---|
Visste du det?
Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).
Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.
Provectus Økonomi
Annual | 2023 |
Omsetning: | $557 710 |
Bruttogevinst: | $548 789 (98.40 %) |
EPS: | $-0.00740 |
FY | 2023 |
Omsetning: | $557 710 |
Bruttogevinst: | $548 789 (98.40 %) |
EPS: | $-0.00740 |
FY | 2022 |
Omsetning: | $989 042 |
Bruttogevinst: | $925 264 (93.55 %) |
EPS: | $-0.00850 |
FY | 2021 |
Omsetning: | $0.00 |
Bruttogevinst: | $0.00 (0.00 %) |
EPS: | $-0.0100 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Provectus
Provectus Biopharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing immunotherapy medicines based on halogenated xanthenes. It develops PV-10, an investigational autolytic cancer immunotherapy for adult solid tumor cancers, such as melanoma and gastrointestinal tumors, including hepatocellular carcinoma; colorectal cancer metastatic to the liver; neuroendocrine tumors metastatic to the liver; uveal melanoma metastatic to the liver; and pediatric solid tumor cancers, such as neuroblastoma, Ewing sarcoma, rhabdomyosarcoma, and osteosarcoma. The company is also developing oral formulations of current good manufacturing practice rose bengal sodium (cGMP RBS) for the treatment of adult solid tumor cancers, such as head and neck, breast, testicular, and colorectal cancers; pediatric blood cancers, including leukemia; coronavirus, an acute respiratory syndrome; multi-drug resistant bacteria, such as gram-negative bacteria; and for eye diseases, including infectious keratitis. In addition, it develops PH-10, an investigational immuno-dermatology agent for the treatment of inflammatory dermatoses, such as psoriasis and atopic dermatitis. The company was formerly known as Provectus Pharmaceuticals, Inc. and changed its name to Provectus Biopharmaceuticals, Inc. in December 2013. Provectus Biopharmaceuticals, Inc. was incorporated in 2002 and is based in Knoxville, Tennessee.
Om Live Signaler
Live Trading signaler pa denne siden er ment til å hjelpe deg i beslutningsprossessen for når du bør KJØPE eller SELGE NA. Signalene har opp mot 1-minutt forsinkelse; som med alle andre indikatorer og signaler, er det en viss sjanse for feil eller feilkalkuleringer.
Live signalene er kun veiledende, og getagraph.com tar ikke noen form for ansvar basert pa handlinger gjort på disse signalene som beskrevet i Terms of Use. Signalene er basert på en rekke indikatorer og påliteligheten vil variere sterke fra aksje til aksje.